This foundational webinar will clarify the science and clinical role of blood-based biomarkers (BBMs) in Alzheimer’s disease (AD). Analytical and clinical performance of AD BBM tests and appropriate positioning of testing within recommended diagnostic pathways alongside cognitive assessment, rule-out labs, and other testing modalities (PET/CSF) will be discussed. Special emphasis will be placed on interpreting positive, indeterminate, and negative test results. Included is a case-based dialogue to address common myths, patient communication tips, and how BBMs enable earlier access to specialist care and potential disease-modifying therapies.

Objectives:

• Differentiate AD BBM tests and key performance characteristics for amyloid pathology detection.
• Identify appropriate clinical use scenarios to order AD BBM tests within a structured diagnostic workup.
• Compare AD BBM tests to PET and CSF for amyloid/tau confirmation.
• Interpret positive, negative and indeterminate test results to guide patient management and patient/caregiver consultations.

• Select an appropriate ordering pathway based on patient presentation and access.
• Apply standardized result interpretation framework to determine diagnostic or patient care next steps.
• Recognize pre-analytical and clinical factors to adjust result interpretation.
• Formulate clear, empathetic patient/caregiver communication including shared decision-making for confirmatory testing and therapy discussions.
  

These educational programs are made possible through the generous support of Fujirebio.

Continuing education credits available for up to 6 months from recording:

• One P.A.C.E.® credit-hour will be provided for this complimentary basic level program. Fujirebio is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program.
• This program is approved for 1 Florida Laboratory CE credit. Florida Board of Clinical Laboratory Personnel approved number: 50-12563